Fig. 2From: Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort studyRelative hazard of ILD using the most specific and sensitive definitions. ABA abatacept, Hx history, ILD interstitial lung disease, MTX methotrexate, RTX rituximab, TCZ tocilizumabBack to article page